NantKwest, Inc. (NASDAQ:NK) Files An 8-K Other Events

NantKwest, Inc. (NASDAQ:NK) Files An 8-K Other Events
Item 8.01

On June 24, 2020, NantKwest, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of an aggregate of 7,410,000 shares of common stock of the Company (the “Underwritten Shares”). The price to the public in the offering is $9.50 per share and the Underwriters have agreed to purchase 3,700,000 of the shares of common stock from the Company to the Underwriting Agreement at a price of $8.93 per share. As part of the offering, the Company’s chairman, chief executive officer and principal stockholder, Dr. Patrick Soon-Shiong is purchasing an aggregate of 3,710,000 shares of the Company’s common stock (the “Affiliated Shares”), which Affiliated Shares are included in the total number of Underwritten Shares. The price to Dr. Soon-Shiong in the offering is $12.12 per share, which price per share is equal to the “market value” of the Company’s common stock immediately preceding the entry into the Underwriting Agreement in accordance with Nasdaq rules. The Underwriters have agreed to purchase the Affiliated Shares from the Company to the Underwriting Agreement at a price of $11.8776 per share.

The net proceeds to the Company from this offering are expected to be approximately $76.4 million, after deducting underwriting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds of the offering for clinical development, manufacturing, upgrades to its facilities and equipment, and for working capital, capital expenditures and other general corporate purposes. The Company has granted the Underwriters a 30-day option to purchase up to an additional 1,111,500 shares of common stock (together with the Underwritten Shares, the “Shares”) at the public offering price of $9.50 per share. The closing of the offering is expected to occur on or about June 29, 2020, subject to the satisfaction of customary closing conditions.

The offering is being made to the Company’s effective registration statement on Form S-3 (Registration Statement No. 333-233434) (the “Registration Statement”) previously filed with the Securities and Exchange Commission and a related prospectus included in the Registration Statement, as supplemented by a preliminary prospectus supplement dated June 24, 2020 and a final prospectus supplement dated June 24, 2020.

The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. In addition, to the terms of the Underwriting Agreement, certain officers and directors of the Company and their affiliated entities have entered into “lock-up” agreements with the Underwriters in substantially the form included as Exhibit A to the Underwriting Agreement, which generally prohibit the sale, transfer or other disposition of securities of the Company for a 90-day period, subject to certain exceptions.

The foregoing description of the Underwriting Agreement is not complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement, a copy of which is filed herewith as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference. A copy of the opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation, relating to the legality of the issuance and sale of the Shares in the offering is filed as Exhibit 5.1 to this Current Report on Form 8-K.

Story continues below

(d) Exhibits.

  1.1    Underwriting Agreement, dated June 24, 2020.
  5.1    Opinion of Wilson Sonsini Goodrich & Rosati, Professional Corporation
23.1    Consent of Wilson Sonsini Goodrich & Rosati, Professional Corporation (contained in Exhibit 5.1)


NantKwest, Inc. Exhibit
EX-1.1 2 d948234dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 NANTKWEST,…
To view the full exhibit click here

About NantKwest, Inc. (NASDAQ:NK)

NantKwest, Inc., formerly Conkwest, Inc., is a biotechnology company engaged in developing targeted direct-acting immunotherapeutic agents for a range of clinical conditions. The Company is focused on harnessing its immune system by using the natural killer (NK) cell to treat cancer, infectious diseases and inflammatory diseases. Its product candidates include activated NK cells (aNK), high-affinity NKs (haNKs) and target activated Natural Killers (taNKs). It develops aNK product candidates for the treatment of virally-induced cancers, such as polyoma virus induced Merkel Cell Carcinoma, Human Papilloma Virus induced cervical, and head and neck cancers, as well as infectious diseases, such as Ebola and other serious viral, fungal and bacterial infections. It also develops haNKs for the treatment of solid tumors, breast cancer, multiple myeloma, lymphoma and colorectal cancer, and taNKs for the treatment of brain cancer, breast cancer, non-hodgkin lymphoma and myelodysplastic syndrome.

An ad to help with our costs